Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Forest Service Accountability Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2026 · first_quarter · Q1
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Proclamation 11020 - Section 232 Pharmaceutical Tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Mikaela Naylon Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1 - Big Beautiful Bill Act
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 Rare Disease Exemption for Most Favored Nation Pricing Proposals
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
Scientific EXPERT Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1532 - Scientific EXPERT Act of 2025 S 822 - Scientific EXPERT Act of 2025
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
Scientific EXPERT Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1532 - Scientific EXPERT Act of 2025 S 822 - Scientific EXPERT Act of 2025
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 Rare Disease Exemption for Most Favored Nation Pricing Proposals
Creating Hope Reauthorization Act of 2024
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
ORPHAN Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
Creating Hope Reauthorization Act of 2024
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2025 · fourth_quarter · Q4
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 Rare Disease Exemption for Most Favored Nation Pricing Proposals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2025 · third_quarter · Q3
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2025 · second_quarter · Q2
HR 1 - Big Beautiful Bill Act
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities
Executive Order 14297 - Impact of EO on Rare Disease Innovation Rare Disease Policy
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2025 · first_quarter · 1A
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024
HR 1532 - Scientific EXPERT Act of 2025 S 822 - Scientific EXPERT Act of 2025
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2025 · first_quarter · RR
Scientific research and education
Scientific research and education
Scientific research and education
Scientific research and education